Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Buy" by Analysts

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has received an average rating of "Buy" from the eight brokerages that are covering the firm, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $19.43.

A number of equities analysts have recently commented on the stock. HC Wainwright lifted their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. BMO Capital Markets upped their price target on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. increased their target price on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th.

Institutional Trading of Replimune Group

A number of institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its stake in shares of Replimune Group by 12.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company's stock valued at $5,313,000 after purchasing an additional 52,498 shares during the period. BNP Paribas Financial Markets grew its position in shares of Replimune Group by 81.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company's stock valued at $165,000 after purchasing an additional 6,748 shares in the last quarter. State Street Corp increased its holdings in shares of Replimune Group by 102.1% in the third quarter. State Street Corp now owns 2,340,042 shares of the company's stock worth $25,647,000 after purchasing an additional 1,182,181 shares during the period. Barclays PLC boosted its stake in Replimune Group by 165.5% during the third quarter. Barclays PLC now owns 158,491 shares of the company's stock valued at $1,738,000 after buying an additional 98,791 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Replimune Group by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company's stock valued at $15,657,000 after acquiring an additional 217,308 shares during the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Replimune Group Price Performance

NASDAQ REPL traded up $0.32 on Friday, hitting $7.83. 471,671 shares of the company's stock were exchanged, compared to its average volume of 866,221. Replimune Group has a 52 week low of $4.92 and a 52 week high of $17.00. The stock has a 50-day moving average of $11.21 and a 200-day moving average of $11.86. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The stock has a market cap of $603.03 million, a price-to-earnings ratio of -2.55 and a beta of 1.26.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Analysts expect that Replimune Group will post -2.97 earnings per share for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.